Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Dechra downgraded to Hold from Buy at Panmure Gordon » 05:10
07/11/22
07/11
05:10
07/11/22
05:10
DCHPF

Dechra Pharmaceuticals

$39.00 /

+ (+0.00%)

Panmure Gordon analyst…

Panmure Gordon analyst Mike Mitchell downgraded Dechra Pharmaceuticals to Hold from Buy with a price target of 3,750 GBp, down from 4,357 GBp. The analyst sees "limited further headroom" on the stock's valuation given increasing cost pressures.

ShowHide Related Items >><<
DCHPF Dechra Pharmaceuticals
$39.00 /

+ (+0.00%)

07/05/22 RBC Capital
Dechra upgraded to Outperform from Sector Perform at RBC Capital
02/23/22 Liberum
Dechra Pharmaceuticals upgraded to Hold from Sell at Liberum
02/21/22 Panmure Gordon
Dechra Pharmaceuticals upgraded to Buy from Hold at Panmure Gordon
01/04/22 JPMorgan
Dechra price target raised to 5,700 GBp from 5,400 GBp at JPMorgan
Upgrade
Dechra upgraded to Outperform from Sector Perform at RBC Capital » 05:19
07/05/22
07/05
05:19
07/05/22
05:19
DCHPF

Dechra Pharmaceuticals

$39.00 /

+ (+0.00%)

RBC Capital analyst Zoe…

RBC Capital analyst Zoe Karamanoli upgraded Dechra Pharmaceuticals to Outperform from Sector Perform with a price target of 4,200 GBp, down from 5,300 GBp. The analyst says Dechra is a "well-run compound growth story" with an attractive valuation at current share levels. The company has strong market trends with revenue that should be defensive in periods of consumer downturn, Karamanoli tells investors in a research note.

ShowHide Related Items >><<
DCHPF Dechra Pharmaceuticals
$39.00 /

+ (+0.00%)

02/23/22 Liberum
Dechra Pharmaceuticals upgraded to Hold from Sell at Liberum
02/21/22 Panmure Gordon
Dechra Pharmaceuticals upgraded to Buy from Hold at Panmure Gordon
01/04/22 JPMorgan
Dechra price target raised to 5,700 GBp from 5,400 GBp at JPMorgan
12/03/21 RBC Capital
Dechra price target raised to 5,300 GBp from 4,400 GBp at RBC Capital
Over a quarter ago
Upgrade
Dechra Pharmaceuticals upgraded to Hold from Sell at Liberum » 05:25
02/23/22
02/23
05:25
02/23/22
05:25
DCHPF

Dechra Pharmaceuticals

$53.45 /

+ (+0.00%)

Liberum analyst Alistair…

Liberum analyst Alistair Campbell upgraded Dechra Pharmaceuticals to Hold from Sell with a 4,020 GBp price target. The analyst believes the company's first half results on Monday should offer support for the shares. He upgrades Dechra to Hold with the stock down 28% year-to-date.

ShowHide Related Items >><<
DCHPF Dechra Pharmaceuticals
$53.45 /

+ (+0.00%)

02/21/22 Panmure Gordon
Dechra Pharmaceuticals upgraded to Buy from Hold at Panmure Gordon
01/04/22 JPMorgan
Dechra price target raised to 5,700 GBp from 5,400 GBp at JPMorgan
12/03/21 RBC Capital
Dechra price target raised to 5,300 GBp from 4,400 GBp at RBC Capital
09/07/21 JPMorgan
Dechra price target raised to 5,400 GBp from 5,200 GBp at JPMorgan
Upgrade
Dechra Pharmaceuticals upgraded to Buy from Hold at Panmure Gordon » 08:22
02/21/22
02/21
08:22
02/21/22
08:22
DCHPF

Dechra Pharmaceuticals

$53.45 /

+ (+0.00%)

Panmure Gordon analyst…

Panmure Gordon analyst Mike Mitchell upgraded Dechra Pharmaceuticals to Buy from Hold with a 4,357 GBp price target.

ShowHide Related Items >><<
DCHPF Dechra Pharmaceuticals
$53.45 /

+ (+0.00%)

01/04/22 JPMorgan
Dechra price target raised to 5,700 GBp from 5,400 GBp at JPMorgan
12/03/21 RBC Capital
Dechra price target raised to 5,300 GBp from 4,400 GBp at RBC Capital
09/07/21 JPMorgan
Dechra price target raised to 5,400 GBp from 5,200 GBp at JPMorgan
09/06/21 Stifel
Dechra Pharmaceuticals downgraded to Hold from Buy at Stifel
Recommendations
Dechra price target raised to 5,700 GBp from 5,400 GBp at JPMorgan » 14:37
01/04/22
01/04
14:37
01/04/22
14:37
DCHPF

Dechra Pharmaceuticals

$67.50 /

+ (+0.00%)

JPMorgan analyst James…

JPMorgan analyst James Gordon raised the firm's price target on Dechra Pharmaceuticals to 5,700 GBp from 5,400 GBp and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
DCHPF Dechra Pharmaceuticals
$67.50 /

+ (+0.00%)

12/03/21 RBC Capital
Dechra price target raised to 5,300 GBp from 4,400 GBp at RBC Capital
09/07/21 JPMorgan
Dechra price target raised to 5,400 GBp from 5,200 GBp at JPMorgan
09/06/21 Stifel
Dechra Pharmaceuticals downgraded to Hold from Buy at Stifel
07/13/21 JPMorgan
Dechra price target raised to 5,200 GBp from 4,200 GBp at JPMorgan
Recommendations
Dechra price target raised to 5,300 GBp from 4,400 GBp at RBC Capital » 15:20
12/03/21
12/03
15:20
12/03/21
15:20
DCHPF

Dechra Pharmaceuticals

$65.90 /

+ (+0.00%)

RBC Capital analyst…

RBC Capital analyst Charles Weston raised the firm's price target on Dechra Pharmaceuticals to 5,300 GBp from 4,400 GBp and keeps a Sector Perform rating on the shares.

ShowHide Related Items >><<
DCHPF Dechra Pharmaceuticals
$65.90 /

+ (+0.00%)

09/07/21 JPMorgan
Dechra price target raised to 5,400 GBp from 5,200 GBp at JPMorgan
09/06/21 Stifel
Dechra Pharmaceuticals downgraded to Hold from Buy at Stifel
07/13/21 JPMorgan
Dechra price target raised to 5,200 GBp from 4,200 GBp at JPMorgan
03/11/21 RBC Capital
Dechra price target raised to 3,600 GBp from 3,450 GBp at RBC Capital
Recommendations
Dechra price target raised to 5,400 GBp from 5,200 GBp at JPMorgan » 12:25
09/07/21
09/07
12:25
09/07/21
12:25
DCHPF

Dechra Pharmaceuticals

$71.50 /

+ (+0.00%)

JPMorgan analyst James…

JPMorgan analyst James Gordon raised the firm's price target on Dechra Pharmaceuticals to 5,400 GBp from 5,200 GBp and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
DCHPF Dechra Pharmaceuticals
$71.50 /

+ (+0.00%)

09/06/21 Stifel
Dechra Pharmaceuticals downgraded to Hold from Buy at Stifel
07/13/21 JPMorgan
Dechra price target raised to 5,200 GBp from 4,200 GBp at JPMorgan
03/11/21 RBC Capital
Dechra price target raised to 3,600 GBp from 3,450 GBp at RBC Capital
11/20/20 RBC Capital
Dechra price target raised to 3,450 GBp from 3,250 GBp at RBC Capital
Downgrade
Dechra Pharmaceuticals downgraded to Hold from Buy at Stifel » 08:23
09/06/21
09/06
08:23
09/06/21
08:23
DCHPF

Dechra Pharmaceuticals

$71.50 /

+ (+0.00%)

Stifel analyst Max…

Stifel analyst Max Herrmann downgraded Dechra Pharmaceuticals to Hold from Buy with a price target of 5,185 GBp, up from 4,900 GBp. The analyst cites valuation for the downgrade, seeing little upside from current share levels.

ShowHide Related Items >><<
DCHPF Dechra Pharmaceuticals
$71.50 /

+ (+0.00%)

07/13/21 JPMorgan
Dechra price target raised to 5,200 GBp from 4,200 GBp at JPMorgan
03/11/21 RBC Capital
Dechra price target raised to 3,600 GBp from 3,450 GBp at RBC Capital
11/20/20 RBC Capital
Dechra price target raised to 3,450 GBp from 3,250 GBp at RBC Capital

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.